- Home
- UTL vs IMMX Comparison
UTL vs IMMX Comparison
Compare UTL & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTL | IMMX |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.1M | 784.8M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UTL | IMMX |
|---|---|---|
| Price | $54.07 | $8.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $54.00 | $24.30 |
| AVG Volume (30 Days) | 126.6K | ★ 1.6M |
| Earning Date | 11-02-2026 | 11-06-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | ★ 1.37 | N/A |
| EPS | ★ 2.11 | N/A |
| Revenue | ★ $536,000,000.00 | N/A |
| Revenue This Year | $16.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.27 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $46.91 | $2.71 |
| 52 Week High | $57.26 | $15.10 |
Technical Indicators
Market Signals| Indicator | UTL | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 65.48 | 27.55 |
| Support Level | $52.10 | $7.96 |
| Resistance Level | $54.96 | $10.61 |
| Average True Range (ATR) | 1.02 | 0.59 |
| MACD | 0.38 | -0.17 |
| Stochastic Oscillator | 93.57 | 1.73 |
Price Performance
Historical ComparisonAbout UTL UNITIL Corporation
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.